Vedolizumab and the gut–CNS axis in multiple sclerosis: considering T cell licensing pathways

While causality cannot be inferred, our findings highlight an opportunity to further explore whether vedolizumab-associated differences in MS prevalence may relate to gut-associated immune processes.

Authors

Institutions

Publication Details

Journal
Therapeutic Advances in Neurological Disorders
Published
2026-02-18
DOI
https://doi.org/10.1177/17562864261423751
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Vedolizumab and the gut–CNS axis in multiple sclerosis: considering T cell licensing pathways

Afsaneh Shirani, Olaf Stuve
Therapeutic Advances in Neurological Disorders
Multiple Sclerosis Research Studies
article

Vedolizumab and the gut–CNS axis in multiple sclerosis: considering T cell licensing pathways

Afsaneh Shirani, Olaf Stuve
article en

Abstract

While causality cannot be inferred, our findings highlight an opportunity to further explore whether vedolizumab-associated differences in MS prevalence may relate to gut-associated immune processes.

Therapeutic Advances in Neurological DisordersVol. 19
Saint Luke's Hospital (US), University of Missouri–Kansas City (US), The University of Texas Southwestern Medical Center (US)
Openalex Percentile: Top 51%
Multiple Sclerosis Research Studies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Vedolizumab and the gut–CNS axis in multiple sclerosis: considering T cell licensing pathways — Afsaneh Shirani, Olaf Stuve · Therapeutic Advances in Neurological Disorders (2026) | TGRS Research Map | TGRS